Document is current

Article History

Received: 22 May 2023

Accepted: 7 July 2023

First Online: 22 August 2023

Declarations

:

: GVL is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, OncoSec, PHMR Ltd, Pierre Fabre, Provectus, Qbiotics, Regeneron. RAS has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. LH has received speaker and consultancy fees from Amgen, BiomeDx, BMS, Curevac, Kyowa Kirin, Merck, MSD, Myoncare, Novartis, Pierre-Fabre, Roche, Sanofi, SUN and Therakos. The LMU received research grants or clinical study grants from Agenus, AstraZeneca Inc., BMS, Hoffmann-La Roche AG, Huya Bioscience, Immunocore, IO Biotech, Merck, Merck Sharp & Dome GmbH, Miltenyi Biomedicine GmbH, Novartis, Pfizer, Pierre Fabre, Regeneron, Replimune, and Sanofi Aventis. The cantonal hospital St. Gallen (TH) received speaker and consultation fees from NovoCure, Amicus therapeutics, Sanofi Genzyme and Bayer AG and an unrestricted research grant from Bayer AG. AMM has served on advisory boards for BMS, MSD, Novartis, Roche, Pierre-Fabre and QBiotics. All remaining authors have declared no conflicts of interest.

: The study was approved by the local ethics committee of the Ludwig Maximilian University Munich, Netherlands Cancer Institute and Melanoma Institute of Australia. All centers were acting according to their regulatory requirements.